Sarepta (SPRT): FDA Request for Dystrophin Data a 'Clear Indication Willing to Grant Accelerated Approval' - Baird

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. USO
2. META
3. NVDA
4. DCOY
5. SPY
6. MSFT
7. VKTX
8. PRGS
9. CMPX
10. GS

Go back to Sarepta (SPRT): FDA Request for Dystrophin Data a 'Clear Indication Willing to Grant Accelerated Approval' - Baird
SAREPTA THERAP (NASDAQ: SRPT) Delayed: 20.81 +0.67 (3.33%)
Previous Close $20.14    52 Week High $63.73 
Open $20.46    52 Week Low $8.00 
Day High $21.19    P/E N/A 
Day Low $20.19    EPS $-5.69 
Volume 2,192,902